Evidence map›Paper›PMID 34994405›Full record

ArticleJournal of surgical oncology2022

Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma.

Paul R Burchard, Alexander C Chacon, Alexa Melucci, Anthony S Casabianca, Subir Goyal, Jeffrey M Switchenko, Shishir K Maithel, David A Kooby, Darren R Carpizo, Mihir M Shah

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Paul R BurchardDivision of General Surgery, Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.ORCID http://orcid.org/0000-0001-7370-5608
Alexander C ChaconDivision of General Surgery, Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Alexa MelucciDivision of General Surgery, Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Anthony S CasabiancaDivision of General Surgery, Department of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Subir GoyalDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Jeffrey M SwitchenkoDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Shishir K MaithelDivision of Surgical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-3591-8925
David A KoobyDivision of Surgical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0001-8694-0455
Darren R CarpizoDivision of Surgical Oncology, Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Mihir M ShahDivision of Surgical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-4665-5534
Emory University · USUniversity of Rochester · USUniversity of Rochester Medical Center · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI MADHAV V DHODAPKAR · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292NIH HHS P30CA138292
6 · The paper itself

Abstract

introductionFollowing resection of pancreatic acinar cell carcinoma (PACC) distant recurrence remains high. We utilized the national cancer database (NCDB) to evaluate the role of systemic therapy in early-stage resected PACC.

methodsWe queried the NCDB registry from 2004 to 2015 for patients with pathologic stage I-IIB PACC. For each stage, patients who underwent surgery alone (SA) were compared to patients who received systemic and/or radiation therapy in addition to surgery (surgery + therapy [S + T]).

resultsA total of 271 patients (101 pI, 81 pIIA, and 89 pIIB) were analyzed. Of all clinically node positive patients (n = 41), the majority (n = 32, 78%) had node-positive disease at resection (pIIB). SA was performed in 112 patients (41.3%), whereas 159 (58.7%) patients received S + T. There was no difference in overall survival (OS) between S + T and SA with respect to pI or pIIA disease. In pIIB disease, S + T was associated with improved OS compared to SA (34.9 vs. 16.9 months, p = 0.031). Single-agent chemotherapy was associated with improved OS for pIIB disease when compared to SA (hazard ratio: 0.38, 95% confidence interval: 0.16, 0.83).

conclusionIn resectable PACC, the survival benefit of adjuvant therapy is limited to pathologic stage IIB disease. This benefit is evident even in patients treated with single-agent chemotherapy.

Indexed as

Carcinoma, Acinar CellPancreatic NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyHumansNeoplasm StagingProportional Hazards Modelschemotherapypancreassurgical oncology

Identifiers

PMID34994405
PMCPMC9082653
OpenAlexW4206761808

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.